Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 30/100

Failure Rate

14.2%

182 terminated/withdrawn out of 1285 trials

Success Rate

83.0%

-3.5% vs industry average

Late-Stage Pipeline

36%

467 trials in Phase 3/4

Results Transparency

73%

644 of 887 completed trials have results

Key Signals

105 recruiting644 with results130 terminated52 withdrawn

Enrollment Performance

Analytics

Phase 3
350(36.1%)
Phase 1
248(25.6%)
Phase 2
217(22.4%)
Phase 4
117(12.1%)
N/A
30(3.1%)
Early Phase 1
7(0.7%)
969Total
Phase 3(350)
Phase 1(248)
Phase 2(217)
Phase 4(117)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (1285)

Showing 20 of 1285 trials
NCT02615184Phase 2Terminated

A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old

Role: lead

NCT03547700Phase 1Terminated

Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL)

Role: collaborator

NCT07403968Phase 2Not Yet Recruiting

A Study of Zasocitinib (TAK-279) in Adults With Active Crohn's Disease

Role: lead

NCT06963827Phase 3Recruiting

A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy

Role: lead

NCT04374305Phase 2Recruiting

Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)

Role: collaborator

NCT06254950Phase 2Active Not Recruiting

A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis

Role: lead

NCT06100289Phase 3Recruiting

A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease

Role: lead

NCT05384080Completed

A Study in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) Receiving Vedolizumab in Real-World Practice in Poland

Role: lead

NCT04779320Phase 3Recruiting

A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)

Role: lead

NCT07251933Recruiting

A Study of Lanadelumab in Children With Hereditary Angioedema (HAE) in Multiple Countries

Role: lead

NCT03173092Phase 4Terminated

A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM)

Role: lead

NCT07263685Not Yet Recruiting

A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE) in the Kingdom of Saudi Arabia

Role: lead

NCT04838522Recruiting

A Study of Prucalopride in Breastfeeding Women With Constipation

Role: lead

NCT07218393Not Yet Recruiting

A Study About the Diagnosis and Management of Hereditary Angioedema (HAE) in Egypt

Role: lead

NCT04940611Completed

A Study of Surgical Interventions in Fistulizing Conditions

Role: lead

NCT06973291Phase 3Completed

A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis

Role: lead

NCT06034925Phase 4Completed

Maribavir vs. Valganciclovir for CMV Prophylaxis in High-Risk Kidney Transplant Recipients

Role: collaborator

NCT04779307Phase 3Completed

A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Ulcerative Colitis (UC)

Role: lead

NCT06948318Phase 3Recruiting

A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

Role: lead

NCT07445087Not Yet Recruiting

A Study of Takhzyro in Teenagers and Adults With Hereditary Angioedema (HAE) in South Korea

Role: lead